Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
Septerna to Present at Bank of America Securities Health Care Conference
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
Septerna to Present at TD Cowen 46th Annual Health Care Conference
Septerna (NASDAQ:SEPN) Stock Price Down 5.9% on Insider Selling
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
Septerna to Participate in 8th Annual Evercore Healthcare Conference
Septerna's Novo Partnership Begins To Transform The Story
Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
Septerna to Participate in Upcoming Investor Conferences
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength?
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
Septerna to Present at Jefferies Global Healthcare Conference
Analysts Think These Stocks Could More Than Double in Value
Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?
Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist
Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
Wall Street Analysts Predict a 207.31% Upside in Septerna, Inc. (SEPN): Here's What You Should Know
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Shareholders to Reach Out